Autologous stem cell transplantation for early type 1 diabetes mellitus

References

• American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2004; 27(Suppl. 1)S5–S10
   PubMedGoogle Scholar
• Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: Estimates for the year 2000 and projections for 2030. Diabetes Care 2004; 27(5)1047–1053
   PubMed Web of Science ®Google Scholar
• Rubin RR, Peyrot M. Quality of life and diabetes. Diabetes Metab Res Rev 1999; 15(3)205–218
   PubMed Web of Science ®Google Scholar
• The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329(14)977–986
   PubMed Web of Science ®Google Scholar
• Onkamo P, Vaananen S, Karvonen M, Tuomilehto J. Worldwide increase in incidence of Type I diabetes–the analysis of the data on published incidence trends. Diabetologia 1999; 42(12)1395–1403
   PubMed Web of Science ®Google Scholar
• Notkins AL, Lernmark A. Autoimmune type 1 diabetes: Resolved and unresolved issues. J Clin Invest 2001; 108(9)1247–1252
   PubMedGoogle Scholar
• Bennett ST, Todd JA. Human type 1 diabetes and the insulin gene: Principles of mapping polygenes. Annu Rev Genet 1996; 30: 343–370
   PubMed Web of Science ®Google Scholar
• Pozzilli P, Di Mario U. Autoimmune diabetes not requiring insulin at diagnosis (latent autoimmune diabetes of the adult): Definition, characterization, and potential prevention. Diabetes Care 2001; 24(8)1460–1467
   PubMed Web of Science ®Google Scholar
• Petrone A, Galgani A, Spoletini M, Alemanno I, Di Cola S, Bassotti G, Picardi A, Manfrini S, Osborn J, Pozzilli P, Buzzetti R. Residual insulin secretion at diagnosis of type 1 diabetes is independently associated with both, age of onset and HLA genotype. Diabetes Metab Res Rev 2005; 21(3)271–275
   PubMedGoogle Scholar
• Pozzilli P, Mesturino CA, Crino A, Gross TM, Jeng LM, Visalli N. Is the process of beta-cell destruction in type 1 diabetes at time of diagnosis more extensive in females than in males?. Eur J Endocrinol 2001; 145(6)757–761
   PubMedGoogle Scholar
• Palmer JP, Fleming GA, Greenbaum CJ, Herold KC, Jansa LD, Kolb H, Lachin JM, Polonsky K S, Pozzilli P, Skyler JS, Steffes MW. C-peptide is the appropriate outcome measure for type 1 diabetes clinical trials to preserve beta-cell function: Report of an ADA workshop, 21–22 October 2001. Diabetes 2004; 53(1)250–264
   PubMedGoogle Scholar
• Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus. Jama 2002; 287(19)2563–2569
   PubMed Web of Science ®Google Scholar
• The Diabetes Control and Complications Trial Research Group. Effect of intensive therapy on residual beta-cell function in patients with type 1 diabetes in the diabetes control and complications trial. A randomized, controlled trial. Ann Intern Med 1998; 128(7)517–523
   PubMedGoogle Scholar
• Bonner-Weir S, Sharma A. Pancreatic stem cells. J Pathol 2002; 197(4)519–526
   PubMed Web of Science ®Google Scholar
• Swenne I. Pancreatic beta-cell growth and diabetes mellitus. Diabetologia 1992; 35(3)193–201
   PubMedGoogle Scholar
• Fernandes A, King LC, Guz Y, et al. Differentiation of new insulin-producing cells is induced by injury in adult pancreatic islets. Endocrinology 1997; 138(4)1750–1762
   PubMed Web of Science ®Google Scholar
• Bonner-Weir S, Trent DF, Weir GC. Partial pancreatectomy in the rat and subsequent defect in glucose-induced insulin release. J Clin Invest 1983; 71(6)1544–1553
   PubMed Web of Science ®Google Scholar
• Finegood DT, Scaglia L, Bonner-Weir S. Dynamics of beta-cell mass in the growing rat pancreas. Estimation with a simple mathematical model. Diabetes 1995; 44(3)249–256
   PubMedGoogle Scholar
• Sako Y, Grill VE. Coupling of beta-cell desensitization by hyperglycemia to excessive stimulation and circulating insulin in glucose-infused rats. Diabetes 1990; 39(12)1580–1583
   PubMedGoogle Scholar
• Bernard C, Berthault MF, Saulnier C, Ktorza A. Neogenesis vs. apoptosis As main components of pancreatic beta cell ass changes in glucose-infused normal and mildly diabetic adult rats. Faseb J 1999; 13(10)1195–1205
   PubMedGoogle Scholar
• Bonner-Weir S, Deery D, Leahy JL, Weir GC. Compensatory growth of pancreatic beta-cells in adult rats after short-term glucose infusion. Diabetes 1989; 38(1)49–53
   PubMed Web of Science ®Google Scholar
• Topp BG, McArthur MD, Finegood DT. Metabolic adaptations to chronic glucose infusion in rats. Diabetologia 2004; 47(9)1602–1610
   PubMedGoogle Scholar
• Kuroda A, Yamasaki Y, Imagawa A. Beta-cell regeneration in a patient with type 1 diabetes mellitus who was receiving immunosuppressive therapy. Ann Intern Med 2003; 139(10)W81
   PubMedGoogle Scholar
• Kang EM, Zickler PP, Burns S, Langemeijer SM, Brenner S, Phang OA, Patterson N, Harlan D, Tisdale JF. Hematopoietic stem cell transplantation prevents diabetes in NOD mice but does not contribute to significant islet cell regeneration once disease is established. Exp Hematol 2005; 33(6)699–705
   PubMed Web of Science ®Google Scholar
• Nelson JL, Torrez R, Louie FM, Choe OS, Storb R, Sullivan KM. Pre-existing autoimmune disease in patients with long-term survival after allogeneic bone marrow transplantation. J Rheumatol Suppl 1997; 48: 23–29
   PubMedGoogle Scholar
• Elliott RB, Crossley JR, Berryman CC, James AG. Partial preservation of pancreatic beta-cell function in children with diabetes. Lancet 1981; 2(8247)631–632
   PubMed Web of Science ®Google Scholar
• Harrison LC, Colman PG, Dean B, Baxter R, Martin FI. Increase in remission rate in newly diagnosed type I diabetic subjects treated with azathioprine. Diabetes 1985; 34(12)1306–1308
   PubMed Web of Science ®Google Scholar
• Cook JJ, Hudson I, Harrison LC, Dean B, Colman PG, Werther GA, Warne GL, Court JM. Double-blind controlled trial of azathioprine in children with newly diagnosed type I diabetes. Diabetes 1989; 38(6)779–783
   PubMedGoogle Scholar
• Silverstein J, Maclaren N, Riley W, Spillar R, Radjenovic D, Johnson S. Immunosuppression with azathioprine and prednisone in recent-onset insulin-dependent diabetes mellitus. N Engl J Med 1988; 319(10)599–604
   PubMed Web of Science ®Google Scholar
• Assan R, Feutren G, Sirmai J, Laborie C, Boitard C, Vexiau P, Du Rostu H, Rodier M, Figoni M, Vague P, et al. Plasma C-peptide levels and clinical remissions in recent-onset type I diabetic patients treated with cyclosporin A and insulin. Diabetes 1990; 39(7)768–774
   PubMedGoogle Scholar
• Bougnères PF, Landais P, Boisson C, Carel JC, Frament N, Boitard C, Chaussain JL, Bach JF. Limited duration of remission of insulin dependency in children with recent overt type I diabetes treated with low-dose cyclosporin. Diabetes 1990; 39(10)1264–1272
   PubMed Web of Science ®Google Scholar
• Herold KC, Hagopian W, Auger JA, Poumian-Ruiz E, Taylor L, Donaldson D, Gitelman SE, Harlan DM, Xu D, Zivin RA, Bluestone J A. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N Engl J Med 2002; 346(22)1692–1698
   PubMed Web of Science ®Google Scholar
• Keymeulen B, Vandemeulebroucke E, Ziegler AG, et al. Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N Engl J Med 2005; 352(25)2598–2608
   PubMed Web of Science ®Google Scholar
• Raz I, Elias D, Avron A, et al. Beta-cell function in new-onset type 1 diabetes and immunomodulation with a heat-shock protein peptide (DiaPep277): A randomised, double-blind, phase II trial. Lancet 2001; 358(9295)1749–1753
   PubMed Web of Science ®Google Scholar
• Saudek F, Havrdova T, Boucek P, et al. Polyclonal anti-T-cell therapy for type 1 diabetes mellitus of recent onset. Rev Diabet Stud 2004; 1(2)80–88
   PubMedGoogle Scholar
• Haller M, Viener H, Brusko T. Insulin requeirements, HbA1c, and stimulated C-peptide following autologous umbilical cord blood transfusion in children with T1D. American Diabetes Association Publisher, Alexandria, Chicago 2007; A82, American Diabetes Association 67th Scientific Sessions
   Google Scholar
• Voltarelli JC, Couri CE, Stracieri AB, et al. Autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus. Jama 2007; 297(14)1568–1576
   PubMed Web of Science ®Google Scholar
• Skyler JS. Cellular therapy for type 1 diabetes: Has the time come? Jama 2007; 297(14)1599–1600
   Google Scholar
• Ross LF, Philipson LH. Ethics of hematopoietic stem cell transplantation in type 1 diabetes mellitus. Jama 2007; 298(3)285–286
   PubMedGoogle Scholar
• Voltarelli J, Couri C, Stracieri A, et al. Ethics of hematopoietic stem cell transplantation in type 1 diabetes mellitus (reply). JAMA 2007; 298: 285–286
   PubMedGoogle Scholar